Get started
Author

Thopisang P. Motlou

SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals
2022 · Simone I. Richardson, Vimbai Sharon Madzorera, et al. · Cell Host & Microbe · 119
PDF
Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner
2021 · Roanne Keeton, Simone I. Richardson, et al. · Cell Host & Microbe · 111
PDF
SARS-CoV-2 exposure in Malawian blood donors: an analysis of seroprevalence and variant dynamics between January 2020 and July 2021
2021 · J Mandolo, J Msefula, et al. · BMC Medicine · 61
PDF
Ad26.COV2.S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS-CoV-2 variants of concern
2022 · Dale Kitchin, Simone I. Richardson, et al. · Cell Reports Medicine · 37
PDF
AstraZeneca COVID-19 vaccine induces robust broadly cross-reactive antibody responses in Malawian adults previously infected with SARS-CoV-2
2022 · Marah G. Chibwana, Thandeka Moyo-Gwete, et al. · BMC Medicine · 24
PDF
Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b–2a trial
2022 · Shabir A Madhi, Gaurav Kwatra, et al. · The Lancet Infectious Diseases · 23
PDF
Shuni Virus in Cases of Neurologic Disease in Humans, South Africa
2021 · Thopisang P. Motlou, Marietjie Venter · Emerging infectious diseases · 21
PDF
Immunogenicity of adjuvanted plant-produced SARS-CoV-2 Beta spike VLP vaccine in New Zealand white rabbits
2023 · Martha M O'Kennedy, Celia Abolnik, et al. · Vaccine · 18
Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants
2024 · Catherine Riou, Jinal N Bhiman, et al. · PLOS Global Public Health · 17
Augmenting glycosylation‐directed folding pathways enhances the fidelity of HIV Env immunogen production in plants
2022 · Emmanuel Margolin, Joel D. Allen, et al. · Biotechnology and Bioengineering · 10
PDF
Epidemiology of Shuni Virus in Horses in South Africa
2021 · Thopisang P. Motlou, June Williams, et al. · Viruses · 10
PDF
Potential Mosquito Vectors for Shuni Virus, South Africa, 2014–2018
2021 · Milehna Mara Guarido, Thopisang Motlou, et al. · Emerging infectious diseases · 7
PDF
SARS-CoV-2 BA.4 infection triggers more cross-reactive neutralizing antibodies than BA.1
2022 · Simone I. Richardson, Thopisang Motlou, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 6
PDF
Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection
2023 · Thandeka Moyo-Gwete, Simone I. Richardson, et al. · PLoS Pathogens · 5
PDF
SARS-CoV-2 BA.4/5 infection triggers more cross-reactive FcγRIIIa signaling and neutralization than BA.1, in the context of hybrid immunity
2024 · Simone I. Richardson, Nonkululeko Mzindle, et al. · Journal of Virology · 2
Durability of ChAdOx1 nCoV-19 (AZD1222) Vaccine and Hybrid Humoral Immunity Against Variants Including Omicron BA.1 and BA.4 Six Months after Vaccination: A Randomised, Phase 1b/2a Trial
2022 · Shabir A. Madhi, Gaurav Kwatra, et al. · SSRN Electronic Journal · 1
SARS-CoV-2 exposure in Malawian blood donors: an analysis of seroprevalence and variant dynamics between January 2020 and July 2021
2021 · Mandolo, J., Msefula, J., et al. · Zenodo (CERN European Organization for Nuclear Research) · 1
Low seroprevalence of neutralizing antibodies to gorilla adenovirus 32 (GRAd32) in southern African populations supports evaluation of this vector platform for HIV vaccine development
2026 · Nonhlanhla N. Mkhize, Anna Patjane, et al. · bioRxiv (Cold Spring Harbor Laboratory)
Works count: 20
Citation count: 474
H-index: 10
I10-index: 11
Year
Topic
Type